SynthesisPloS one2019

Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma.

Gabriel Tremblay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.